In this episode, Will Tjernlund speaks with Dr. Bill Williams, President and CEO of BriaCell Therapeutics, a clinical-stage immuno-oncology company trading under the ticker BCTX.

Dr. Williams discusses his transition from academia to the biotechnology industry, his role in advancing the blockbuster drug Jakafi, and why he personally invested millions of dollars in BriaCell alongside Chairman Jamieson Bondarenko.

The conversation explores BriaCell’s lead candidate, Bria-IMT, an investigational immunotherapy being evaluated in late-stage metastatic breast cancer patients who have exhausted other treatment options. Dr. Williams explains how BriaCell genetically modifies cancer cells to stimulate a targeted immune response and discusses the company’s ongoing Phase 3 program.

They also cover BriaCell’s personalized, off-the-shelf Bria-OTS platform, early clinical observations, the company’s expansion into prostate, lung, ovarian, and other cancers, and the potential commercialization paths available if its clinical programs are successful.

Learn more about BriaCell Therapeutics and its pipeline at the company’s website.

Ticker: BCTX

This conversation is for informational purposes only and should not be considered investment or medical advice.

BriaCell Website: https://briacell.com/

Nano Cap Podcast: https://www.nanocappod.com/

DISCLAIMER - The contents of this podcast are for informational purposes only and do not constitute financial, investment, legal, or other professional advice. Listeners should not construe any information discussed as a recommendation to buy, sell, or hold any securities or investments. Always consult with a qualified financial advisor or professional before making any financial decisions.